{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T21:51:04Z","timestamp":1751406664214,"version":"3.37.3"},"reference-count":24,"publisher":"FapUNIFESP (SciELO)","issue":"3","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Assoc. Med. Bras."],"abstract":"<jats:p>SUMMARY Malignant liver tumors are the fourth leading cause of cancer death worldwide. Hepatocellular carcinoma (HCC) accounts for 75-85% of these. Most patients are diagnosed at incurable stages. Palliative care is the appropriate treatment course in these circumstances (chemoembolization and sorafenib). There are few national studies on sorafenib. The objective is to evaluate survival predictors of HCC patients treated with sorafenib and evaluate the compliance of its indication in relation to BCLC recommendations.  METHODS  A total of 88 patients with an indication of sorafenib from 2010 to 2017 at the ISCMSP were retrospectively analyzed. Univariate and multivariate analyzes were performed in the search for predictors of survival.  RESULTS  The mean age was 61.2 years, 70.5% were men, most were classified as Child-Pugh A (69.3%), and BCLC C (94.3%). Cirrhosis was present in 84.6% and portal hypertension in 55.7%. Hepatitis C virus was the most common etiology (40.9%). Sixty-nine (78.4%) patients received the medication, with the average duration of treatment being 9.7 months. The mean overall survival was 16.8 months. Significant differences were observed in the multivariate analysis: ECOG PS (p = 0.024): Child-Pugh (p = 0.013), time of medication use (p &lt;0.001), clinical worsening (p = 0.031) and portal thrombosis (p = 0.010).  CONCLUSION  Absence of portal thrombosis, Child-Pugh A, longer time of medication use, ECOG PS 0, and absence of suspension due to clinical worsening were predictors of better overall survival in the study. The drug\u2019s indication complies with BCLC guidelines in 94% of patients.<\/jats:p>","DOI":"10.1590\/1806-9282.66.3.275","type":"journal-article","created":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T12:40:36Z","timestamp":1591188036000},"page":"275-283","source":"Crossref","is-referenced-by-count":1,"title":["Overall survival predictors in hepatocellular carcinoma patients treated with sorafenib"],"prefix":"10.1590","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4318-4343","authenticated-orcid":false,"given":"Caroline Petersen da Costa","family":"Ferreira","sequence":"first","affiliation":[{"name":"Irmandade da Santa Casa de Miseric\u00f3rdia de S\u00e3o Paulo,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4876-2242","authenticated-orcid":false,"given":"Mauricio Alves","family":"Ribeiro","sequence":"additional","affiliation":[{"name":"Irmandade da Santa Casa de Miseric\u00f3rdia de S\u00e3o Paulo,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1529-0579","authenticated-orcid":false,"given":"Luiz Arnaldo","family":"Szutan","sequence":"additional","affiliation":[{"name":"Irmandade da Santa Casa de Miseric\u00f3rdia de S\u00e3o Paulo,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","published-online":{"date-parts":[[2020,3]]},"reference":[{"key":"ref1","series-title":"Global cancer statistics 2018 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","first-page":"394","volume":"68","author":"Bray F","year":"2018"},{"issue":"2","key":"ref2","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S2468-1253(16)30161-3","article-title":"Characteristics, management, and outcomes of patients with hepatocellular carcinoma in Africa: a multicountry observational study from the Africa Liver Cancer Consortium","volume":"2","author":"Yang JD","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"ref3","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/liv.13502","article-title":"Hepatocellular carcinoma in South America: evaluation of risk factors, demographics and therapy","volume":"38","author":"Debes JD","year":"2018","journal-title":"Liver Int"},{"issue":"10","key":"ref4","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1158\/1535-7163.MCT-08-0013","article-title":"Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling","volume":"7","author":"Wilhelm SM","year":"2008","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"ref5","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/FPC.0000000000000279","article-title":"PharmGKB summary: sorafenib pathways","volume":"27","author":"Gong L","year":"2017","journal-title":"Pharmacogenet Genomics"},{"issue":"4","key":"ref6","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet J","year":"2008","journal-title":"Engl J Med"},{"issue":"1","key":"ref7","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng AL","year":"2009","journal-title":"Lancet Oncol"},{"issue":"3","key":"ref8","doi-asserted-by":"crossref","first-page":"445","DOI":"10.3851\/IMP2602","article-title":"Clinical and epidemiological aspects of hepatocellular carcinoma in Brasil","volume":"18","author":"Kikuchi L","year":"2013","journal-title":"Antivir Ther"},{"issue":"8","key":"ref9","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/bjs.1800600817","article-title":"Transection of the oesophagus for bleeding oesophageal varices","volume":"60","author":"Pugh RN","year":"1973","journal-title":"Br J Surg"},{"year":"1964","series-title":"The liver and portal hypertension","author":"Child CG","key":"ref10"},{"issue":"6","key":"ref11","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken MM","year":"1982","journal-title":"Am J Clin Oncol"},{"issue":"3","key":"ref12","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.24199","article-title":"Management of hepatocellular carcinoma: an update","volume":"53","author":"Bruix J","year":"2011","journal-title":"Hepatology"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"275","DOI":"10.4236\/jct.2016.74029","article-title":"Better management of adverse events favors sorafenib treatment of HCC patients and impact on survival","volume":"7","author":"Alencar RSSM","year":"2016","journal-title":"J Cancer Ther"},{"issue":"2","key":"ref14","first-page":"366","article-title":"Sub-classification of advance-stage hepatocellular carcinoma: a cohort study including 612 patients treated with sorafenib","volume":"50","author":"Yoo JJ","year":"2017","journal-title":"Cancer Res Treat"},{"issue":"6","key":"ref15","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.jhep.2016.07.020","article-title":"Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: the GIDEON study","volume":"65","author":"Marrero JA","year":"2016","journal-title":"J Hepatol"},{"issue":"10","key":"ref16","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1111\/j.1365-2036.2011.04860.x","article-title":"Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score","volume":"34","author":"Hollebecque A","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"ref17","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jhep.2012.06.014","article-title":"Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial","volume":"57","author":"Bruix J","year":"2012","journal-title":"J Hepatol"},{"issue":"9","key":"ref18","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/j.1872-034X.2012.00991.x","article-title":"Skin toxicities and survival in advanced hepatocellular carcinoma patients treated with sorafenib","volume":"42","author":"Otsuka T","year":"2012","journal-title":"Hepatol Res"},{"issue":"6","key":"ref19","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1002\/hep.24644","article-title":"Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy","volume":"54","author":"Iavarone M","year":"2011","journal-title":"Hepatology"},{"key":"ref20","doi-asserted-by":"crossref","DOI":"10.1186\/s12876-016-0464-x","article-title":"Evaluation of dose-efficacy of sorafenib and effect of transarterial chemoembolization in hepatocellular carcinoma patients: a retrospective study","volume":"16","author":"Hsiao WD","year":"2016","journal-title":"BMC Gastroenterol"},{"issue":"6","key":"ref21","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1159\/000439079","article-title":"Real-life clinical practice with sorafenib in advanced hepatocellular carcinoma: a single-center experience second analysis","volume":"33","author":"Arizumi T","year":"2015","journal-title":"Dig Dis"},{"issue":"19","key":"ref22","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1158\/1078-0432.CCR-16-0919","article-title":"Sorafenib in patients with hepatocellular carcinoma-results of the observational INSIGHT study","volume":"23","author":"Ganten TM","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"1","key":"ref23","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1634\/theoncologist.2009-0143","article-title":"Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib","volume":"15","author":"Vincenzi B","year":"2010","journal-title":"Oncologist"},{"issue":"2","key":"ref24","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jhep.2014.03.030","article-title":"Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib","volume":"61","author":"Reig M","year":"2014","journal-title":"J Hepatol"}],"container-title":["Revista da Associa\u00e7\u00e3o M\u00e9dica Brasileira"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/ramb\/v66n3\/1806-9282-ramb-66-3-0275.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,23]],"date-time":"2021-01-23T20:14:30Z","timestamp":1611432870000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0104-42302020000300275&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":24,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,3]]}},"alternative-id":["S0104-42302020000300275"],"URL":"https:\/\/doi.org\/10.1590\/1806-9282.66.3.275","relation":{},"ISSN":["1806-9282","0104-4230"],"issn-type":[{"type":"electronic","value":"1806-9282"},{"type":"print","value":"0104-4230"}],"subject":[],"published":{"date-parts":[[2020,3]]}}}